Markets:

Overview

News

Currencies

International

Treasuries

Ascendis Pharma A/S - Ordinary Share (NQ:ASND)

220.75 -16.72 (-7.04%)

Streaming Delayed Price Updated: 12:27 PM EDT, May 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - Ordinary Share

< Previous 1 2 3 4 5 6 7 8 9 Next >

Expert Ratings for Ascendis Pharma ↗

September 22, 2022

Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings:

Via Benzinga

Ascendis Seeks FDA Nod For TransCon PTH In Adults With Hypoparathyroidism ↗

August 31, 2022

Ascendis Pharma (NASDAQ: ASND) has submitted a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for TransCon PTH, an investigational pro-drug designed to restore parathyroid...

Via Benzinga

Expert Ratings for Ascendis Pharma ↗

August 30, 2022

Analysts have provided the following ratings for Ascendis Pharma (NASDAQ:ASND) within the last quarter:

Via Benzinga

Oppenheimer Maintains Outperform Rating for Ascendis Pharma: Here's What You Need To Know ↗

August 11, 2022

Oppenheimer has decided to maintain its Outperform rating of Ascendis Pharma (NASDAQ:ASND) and lower its price target from $154.00 to $144.00. Shares of Ascendis Pharma are trading up 8.7% over the...

Via Benzinga

Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial ↗

August 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

What 14 Analyst Ratings Have To Say About Ascendis Pharma ↗

May 12, 2022

Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings:

Via Benzinga

Where Ascendis Pharma Stands With Analysts ↗

January 27, 2022

Over the past 3 months, 4 analysts have published their opinion on Ascendis Pharma (NASDAQ:ASND) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

Ascendis Slammed After Growth Hormone Drug Faces An Unexpected Challenge ↗

May 12, 2022

Ascendis Pharma sells a treatment for children with insufficient growth hormone.

Via Investor's Business Daily

The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL ↗

March 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

BofA Upgrades Ascendis Pharma After Promising TCP Phase 3 Data ↗

March 15, 2022

Following Ascendis Pharma’s (NASDAQ: ASND) reporting of positive topline Phase III data for its PaTHway trial of TransCon PTH (TCP) in adults with hypoparathyroidism, the...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022 ↗

March 15, 2022

Upgrades For Turquoise Hill Resources Ltd (NYSE:TRQ), BMO Capital upgraded the previous rating of Underperform to Market Perform. Turquoise Hill Resources earned $0.78 in the...

Via Benzinga

Where Ascendis Pharma Stands With Analysts ↗

January 06, 2022

Analysts have provided the following ratings for Ascendis Pharma (NASDAQ:ASND

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 14, 2022

Gainers Erytech Pharma (NASDAQ:ERYP) stock rose 18.7% to $1.65 during Monday's pre-market session. The market value of their outstanding shares is at $51.1 million....

Via Benzinga

10 Biggest Price Target Changes For Monday ↗

March 14, 2022

Wells Fargo raised the price target on Laredo Petroleum, Inc. (NYSE: LPI) from $72 to $113. Laredo Petroleum shares fell 2.8% to $71.00 in pre-market trading.

Via Benzinga

Ascendis Pharma's Hypoparathyroidism Trial Meets Primary, Secondary Endpoints ↗

March 14, 2022

Ascendis Pharma A/S (NASDAQ: ASND) announced topline data from its Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism (HP), a condition in...

Via Benzinga

7 Biotech Stocks With Key Catalysts in March ↗

March 09, 2022

These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways.

Via InvestorPlace

Analyst Ratings For Ascendis Pharma ↗

November 11, 2021

Analysts have provided the following ratings for Ascendis Pharma (NASDAQ:ASND

Via Benzinga

Expert Ratings For Ascendis Pharma ↗

March 07, 2022

Within the last quarter, Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...

Via Benzinga

The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO ↗

March 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis...

Via Benzinga

Pfizer Dives After FDA Rejects Its OPKO-Partnered Rare Disease Treatment ↗

January 24, 2022

Pfizer stock tumbled after the FDA rejected an OPKO-partnered drug.

Via Investor's Business Daily

Ascendis Pharma's Growth Hormone Deficiency Med Scores European Approval ↗

January 13, 2022

The European Commission (EC) has granted marketing authorization to Ascendis Pharma A/S's (NASDAQ: ASND) Lonapegsomatropin (developed under the name TransCon hGH)....

Via Benzinga

The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial ↗

November 19, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic Dermatitis Treatment Aces Mid-stage Study But Lack...

Via Benzinga

Earnings Scheduled For March 2, 2022 ↗

March 02, 2022

Companies Reporting Before The Bell • SIGNA Sports United (NYSE:SSU) is expected to report quarterly loss at $0.04 per share on revenue of $283.61 million. •...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022 ↗

March 01, 2022

Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,...

Via Benzinga

Ascendis' Hypoparathyroidism Candidate Shows Durable Benefit At 84 Weeks ↗

November 19, 2021

Ascendis Pharma A/S (NASDAQ: ASND) announced topline results from Week 84 of its Phase 2 PaTH Forward Trial of its TransCon PTH candidate hypoparathyroidism (HP)....

Via Benzinga

10 Biggest Price Target Changes For Monday ↗

November 15, 2021

Keybanc boosted the price target on Netflix, Inc. (NASDAQ: NFLX) from $690 to $725. Netflix shares rose 0.2% to $683.90 in pre-market trading. Piper Sandler raised the price...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For February 14, 2022 ↗

February 14, 2022

Upgrades According to Mizuho, the prior rating for Murphy Oil Corp (NYSE:MUR) was changed from Neutral to Buy. In the fourth quarter, Murphy Oil showed an EPS of $0.40,...

Via Benzinga

Ascendis Pharma A/S (ASND) Q3 2021 Earnings Call Transcript ↗

November 10, 2021

ASND earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2022 ↗

January 06, 2022

Upgrades For Canada Goose Holdings Inc (NYSE:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021 ↗

December 08, 2021

Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.